Skip to main content
SpringerLink
Log in

Oral iron chelation: A review with special emphasis on Indian work on deferiprone (L1)

  • Symposium: Hematology/Oncology—II
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kontoghiorghes GJ. New orally active iron chelators.Lancet 1985; 1: 817.

    Article  PubMed  CAS  Google Scholar 

  2. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl 3-hydroxypyrid-4-one (L1). II Clinical Observations.Br J Haematology 1990; 76: 301–304.

    CAS  Google Scholar 

  3. Olivieri NF, G, Koran C, St Louis P et al. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.Semin Hematol 1990; 27: 101–104.

    PubMed  CAS  Google Scholar 

  4. Toendury P, Kontoghiorghes GJ, Ridolfi-Luthy A et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for iron chelation in patients with beta-oral major.Br J Haematol 1990; 76: 550–553.

    Google Scholar 

  5. Agarwal MB, Viswanathan C, Ramananthan J et al. Oral iron chelation with L1 (letter).Lancet 1990; 335: 601.

    Article  PubMed  CAS  Google Scholar 

  6. Agarwal MB, Gupta SS, Vasandani D. Efficacy and safely of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassemia major with iron overload.Journal Assoc Phys of India 1991; 39: 669–672.

    CAS  Google Scholar 

  7. Agarwal MB, Gupta SS, Vishwanathan C et al. Long term assessment of efficacy and safely of L1. an oral iron chelator, in transfusion dependent thalassemia India trial.Br J Haematol 1992; 82: 460–466.

    PubMed  CAS  Google Scholar 

  8. Kontoghiorghes GJ. L1. 1,2-dimethyl-3-hydroxypyrid-4-one.Drugs of the Future 1988; 13: 413–415.

    Google Scholar 

  9. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV et al. Effective chelation of iron in beta thalassemia with the oral chelator 1, 2-dimethyl-3-hydroxyphrid-4-one.Br Med J 1987; 295: 1509–1512.

    Article  CAS  Google Scholar 

  10. Mehta J, Singhal S, Revankar R et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 (letter).Lancet 1991; 337: 298.

    Article  PubMed  CAS  Google Scholar 

  11. Hoffbrand AV, Bartlett AN, Veys PA et al. Agranulocytosis and thrombocytopenia in a patient with Blackfan-Diamond anaemia during oral chelator trial (letter).Lancet 1989; 2: 457.

    Article  PubMed  CAS  Google Scholar 

  12. Kontoghiorghes GJ et al. Safety of oral iron chelator L1.Lancet 1989; 2: 457.

    Article  CAS  Google Scholar 

  13. Kontoghiorghes GJ, Nasseri-Sina P, Goddard JG et al. Safety of oral iron chelator L1 (letter).Lancet 1989; 2: 4578.

    Google Scholar 

  14. Kontoghiorghes GJ. Advances in oral iron chelation in man: A review.Int J Hematol 1992; 55: 27–38.

    PubMed  CAS  Google Scholar 

  15. Kontoghiorghes GJ. Updated report on the worldwide oral iron chelation therapy with L1-deferiprone and ketohydroxypyridone (abstract).5th Int Conf on Thalassemia and Haemoglobinopthies held at Cyprus, 1993; pp. 111.

  16. Agarwal MB, Gupta SS, Vishwanathan C et al. Long term efficacy and toxicity of L1-oral iron chelation in transfusion dependent thalassemics over the last three years (1989–92) (abstract):5th Int Conf on Thalassemia and Haemoglobinopathies held at Cyprus. 1993; pp. 192.

  17. Agarwal MB.Living with Thalassemia. Bombay: Bhalani Book Dept, 1986.

    Google Scholar 

  18. Grady RW, Graziano JH, White GP et al. The development of new iron chelating drugs (ii).Journal of Pharmacology and Experimental Therapeutics 1978; 205: 757–765.

    CAS  Google Scholar 

  19. Olivieri NF, Koren G, Klein J et al. Oral iron chelation with 1,2-dimethyl-3-hydroxypyride-4-one (L1) in thalassemia major (TM): pharmacokinetics, safety and iron excretion.Blood Suppl 1990; 76: 277.

    Google Scholar 

  20. Hider RC, Singh S, Porter JB et al. The development of hydroxypyridin-4-ones as orally active iron chelators.Ann NY Acad Sci 1990; 612: 327–338.

    Article  PubMed  CAS  Google Scholar 

  21. Kontoghiorghes GJ. The study of iron mobilization from transferrin using alpha-ketohydroxy heteroaromatic chelatores.Biochim Biophys Acta 1986; 869: 141–146.

    PubMed  CAS  Google Scholar 

  22. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV et al. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) I. Iron chelation and metabolic studies.Br J Haematol 1990; 76: 295–300.

    PubMed  CAS  Google Scholar 

  23. Kontoghiorghes GJ, Aldouri MA, Sheppard L et al. 1,2, dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.Lancet 1987; 1: 1294–1295.

    Article  PubMed  CAS  Google Scholar 

  24. Kontoghiorghes GJ, Goddard JG, Bartlett AN et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.Clin Pharmacol Ther 1990; 48: 255–261.

    PubMed  CAS  Google Scholar 

  25. Matsui D, Klein J, Hermann C et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.Clin Pharmacol Ther 1991; 50: 294–298.

    Article  PubMed  CAS  Google Scholar 

  26. Mehta J, Singhal S, Chablani A et al. L1-induced systemic lupus erythematosus.Indian J Hematol Blood Transf 1991; 9: 33–37.

    Google Scholar 

  27. Olivieri NF, Koren G, Freedman MH et al. Rarity of systemic lupus erythematosus in patients taking L1.Lancet 1991; 337: 924.

    Article  PubMed  CAS  Google Scholar 

  28. Agarwal MB, Vishwanathan C, Gupta SS et al. Antinuclear antibody positivity in multi-transfused thalassemia major.Indian Pediatr 1992; 29: 607–610.

    PubMed  CAS  Google Scholar 

  29. Editorial. Oral iron chelators.Lancet 1989; 1: 1016–1017.

  30. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alphaketohydroxypyridines. In:Advances and Controversies in Thalassemia Bone Marrow Transplantation and Other Approaches. New York: Alan R. Liss Inc. 1989; 107–114.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, L.T.M.G. Hospital and L.T.M. Medical College, Sion, Bombay

    M. B. Agarwal

Authors
  1. M. B. Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agarwal, M.B. Oral iron chelation: A review with special emphasis on Indian work on deferiprone (L1). Indian J Pediatr 60, 509–516 (1993). https://doi.org/10.1007/BF02751427

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02751427

Keywords

Search

Navigation